WallStreetZenWallStreetZen

NYSEMKT: CANF
Can Fite Biopharma Ltd Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

CANF past revenue growth

How has CANF's revenue growth performed historically?
Company
13.83%
Industry
58.31%
Market
17.32%
CANF's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CANF's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CANF's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CANF earnings and revenue history

Current Revenue
$864.0k
Current Earnings
-$12.1M
Current Profit Margin
-1,405.4%

CANF Return on Equity

Current Company
-175.4%
Current Industry
3.9%
Current Market
22.1%
CANF's Return on Equity (-175.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CANF announces earnings.

CANF Return on Assets

Current Company
-99.4%
Current Industry
3.3%
CANF is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CANF Return on Capital Employed

Current Company
-96.43%
Current Industry
9.5%
CANF's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CANF vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CANF$864.00k-$12.13M-$12.14M+36.04%N/A
OGEN$218.51k-$16.23M-$16.28MN/AN/A
SNGX$858.50k-$14.91M-$14.75M-31.86%N/A
VLON$0.00-$6.84M-$7.02M-100.00%N/A
ATXI$0.00-$4.62M-$4.71MN/AN/A
View Top Biotech Stocks

Can Fite Biopharma Earnings & Revenue FAQ

What were CANF's earnings last quarter?

Can Fite Biopharma (NYSEMKT: CANF) reported Q2 2022 earnings per share (EPS) of N/A, up N/A year over year. Total Can Fite Biopharma earnings for the quarter were N/A. In the same quarter last year, Can Fite Biopharma's earnings per share (EPS) was -$3.00.

If you're new to stock investing, here's how to buy Can Fite Biopharma stock.

What was CANF's earnings growth in the past year?

As of Q1 2023, Can Fite Biopharma's earnings has grown year over year. Can Fite Biopharma's earnings in the past year totalled -$12.14 million.

What was CANF's revenue last quarter?

Can Fite Biopharma (NYSEMKT: CANF) reported Q2 2022 revenue of N/A up N/A year over year. In the same quarter last year, Can Fite Biopharma's revenue was $250.00 thousand.

What was CANF's revenue growth in the past year?

As of Q1 2023, Can Fite Biopharma's revenue has grown 13.83% year over year. This is 44.48 percentage points lower than the US Biotechnology industry revenue growth rate of 58.31%. Can Fite Biopharma's revenue in the past year totalled $864.00 thousand.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.